Neovascularisation is the biological process of forming new blood vessels. 
Neovascularisation is the biological process of forming new blood vessels. It occurs in nearly every tissue and in a variety of normal and pathological conditions which can develop acutely, such as following trauma, or chroni cally, as a complication of diseases such as diabetes. Ischaemia is an important condition which contributes to initiating neovascular isation in many situations. Microscopically, neovascularisation develops as a series of sequential steps involving several types of cells with the microvascular endothelial cell having the dominant role. As reviewed by Folkman and Klagsburn/ new capillaries ori· ginate mainly at sites of local degradation of the basement membrane which surrounds the microvascular endothelial cells (Figure 1 ).
Endothelial cells then extend cytoplasmic buds through the gaps in the basement memo brane, elongate, and align with one anotherin the direction of chemotactic factors to form an endothelial capillary sprout. Mitosis of endo· Growth factors and normal neovascularisation. Following an initial event such as ischaemic injury vascular endothelial cells extend buds throug h breaks in the basement memb rane in the direction of chemotactic factors . The bu ds extend by mitosis which is stimulated by peptide growth factors , the new endothelial cells form l umens , and merg e at their tips to form new capillary loops which are stab ilised by inhib itory grow th factors produced by pericytes when they are in contact with endothelial cells.
thelial cells further extends the sprout and a small lumen forms by curvature within each endothelial cell. Two hollow sprouts eventu ally join at their tips to form a loop after which blood flow begins. Pericytes migrate along the new loop structure, and complete the process of normal neovascularisation.
An understanding of the steps of neovas cularisation at the microscopic level has allowed development of in vitro assays which model four of the key processes: (i) enzymatic degradation of basement membrane; (ii) chemotaxis and migration of endothe lial cells; (iii) endothelial cell mitosis; (iv) interaction of endothelial cells and peri cytes. Utilising these in vitro assays, samples of fluids and tissue homogenates have been examined, and several peptide growth factors as well as several nonpeptide factors have been identified which dramatically influence the process of neovascularisation. Some of the most important concepts which emerged from these molecular studies are: (i) a number of different peptide growth factors can stimulate processes of neo vascularisation in vitro and in vivo; (ii) different peptide growth factors may act directly or indirectly to influence neovascularisation; (iii) neovascularisation is not regulated solely by the presence or absence of stimulatory factors but by the balance of various stimulatory and inhibitory factors; (iv) endothelial cells interact with pericytes to regulate neovascularisation locally. One of the most studied conditions of abnormal neovascularisation in the eye is dia betic retinopathy. For more than a century it has been postulated that humoral substances produced by retina cells under the influence of anoxia lead to the formation of new vessels in the retina. 2 ,3 Early in vitro experiments demonstrated that aliquots of vitrectomy fluid from human eyes with neovascularisation stimulated blood vessel growth on the chick chorioallantonic membrane and stimulated endothelial cell division,4 As vitreous samples from normal eyes were studied further, both stimulatory and inhibitory angiogenic activi ties were detected suggesting that it is an imbalance of these activities that leads to neo vascularisation in diabetic patients. Thus, the presence of one or more peptide growth fac tors in elevated levels or insufficient levels of inhibitory factors may shift the delicate balance from an inhibitory to a stimulatory environment for neovascularisation.
Biochemical Properties and Biological Action of Angiogenic Peptide Growth Factors
A number of angiogenic substances have been discovered during recent years, and some have been biochemically characterised and identified, These include very low molecular weight materials (less than 100 m,w,), pep tides and proteins in the range of 2,000 to 30,000 m. W., and lipid-like materials includ ing prostaglandins PGEp and PGE 2 , The very low molecular weight substances remain largely uncharacterised and the mechanism of action of prostaglandins in stimulating neo vascularisiation remains unclear. Focussing on the peptides and proteins, most of these activities have been biochemically identified and are listed in Table I , along with a general summary of their action on endothelial cell mitoses and chern otosis in vitro,
Heparin Binding Growth Factors
Among the first peptide growth factors to be recognised as potent mitogens of vascular endothelial cells are the family of heparin binding growth factors (HBGF), As reviewed by Lobb, Harper and Fett,5 their name implies that these peptides share an affinity for heparin which, besides aiding in their puri fication, probably is important in their physio logical action in neovascularisation, This family of factors includes a number of homog enous peptides isolated from different tissues and species, However, all the HBGF can be grouped into one of two classes based on their isoelectric point (pI) and the conditions required for elution from heparin-Sepharose.
Class 1 HBGF elute with 1 M sodium chlo ride at pH 7 and have pIs of approximately five, The parent molecule has 140 amino acids and a molecule weight of about 15,000. Class 1 HBGFs have been found almost exclusively in neural tissue such as brain, hypothalamus The parent molecules of the two classes appear to be proteolytically processed to gen erate the different members of the two classes. The amino acid sequences of the parent molecules of the two classes of HBGF share about 50% absolute sequence homol ogy. Recently, the putative receptor for both acidic and basic FGFs was identified and found to be a single chain, transmembrane protein with tyrasine kinase activity.6 FGF is a potent mitogen for cultures of ret inal derived vascular endothelial cells.7 In addition, FGF is a chemoattractant for endo thelial cells and will stimulate neovascular isation in several in vivo assays including corneal implant assay.8 The production of bFGF by bovine capillary endothelial cells in culture implicates FGF in the regulation of neovascularisation.9 In addition, FGF has been localised in the basement membrane of capillaries where it is presumed to be bound in an inactive state to heparin. IO This obser vation raises the interesting possibility that, following an injury to the capillaries, latent FGF in the basement membrane is released and rapidly stimulates the initiation of neovascularisation by its action on endothelial cells, pericytes and fibroblasts. Thus, this local reservoir of latent FGF is activated immediately following injury to begin the pro cess of neovascularisation and does not require several hours before neovascular growth factor mRNA and protein could be synthesised by viable cells in the wound site.
More direct in vivo experiments recently demonstrated the effect of FGF and ischae mia on retinal capillary endothelial cell DNA synthesis.!! FGF was injected into the vitreous cavity of cats along with tritiated thymidine and mitosis of retinal vascular endothelial cells was measured by counting labelled nuclei of endothelial cells. Endothelial cells in retinas of eyes treated with FGF contained large numbers of labelled nuclei compared to control eyes. In a second experiment, local retinal ischaemia was produced by branch vein occlusion and spontaneous DNA syn thesis was assessed by uptake of tritiated thy midine. Intense nuclear labelling was seen within the distribution of the occluded vein but not in the areas outside the occluded vein. These results demonstrated the powerful effects of FGF on endothelial cell mitosis and emphasise the importance of ischaemia on the initiation of localised neovascularisation.
Clinical studies also have suggested that FGF is involved in retinal neovascularisation. Levels of bFGF were recently reported in vit reous of 36 patients undergoing vitrectomy for a variety of retinal conditions including proliferative diabetic retinopathy, macular degeneration, and retinal detachment with and without proliferative vitreoretinopathy. !2 Approximately half of the 17 patients with proliferative diabetic retinopathy had ele vated (>30 ng/ml) levels of bFGF in the vit reous, and six of the eight patients with active proliferative retinopathy had elevated FGF levels compared to two of seven with inactive disease. These elevated levels of bFGF are sufficient to stimulate DNA synthesis of endo thelial cells in vitro. Thus, FGF appears to play key roles in regulating several steps of neovascularisation.
Insulin-Like Growth Factors
Insulin-like growth factor I (IGF-I) is a single chain protein of 70 amino acids which is a member of a family of peptides that share sub stantial sequence homology to proinsulin. Other members of the family include insulin like growth factor II (IGF-II) and relaxin. IGF-I, known previously as somatomedin C, is now recognised to stimulate many of the cellular effects originally attributed to the action of growth hormone. 13 Evdience has led to a dual effector theory of IGF-I and growth hormone action which proposes that growth hormone first causes cell differentiation then IGF-I acts as the mitotic signal to stimulate division of these newly differentiated cells. Thus, IGF-I may act in concert with pituitary growth hormone to influence mitosis of cells.
Serum levels of IGF-I primarily reflect hepatic synthesis which is regulated predom inantly by the action of growth hormone derived from the pituitary. Unlike other pep tide growth factors, IGF-I is bound in blood and other physiologic fluids to specific binding proteins which prolong the lifetime of IGF-I in blood and modulate the biological activity of IGF_Ll4-16 In blood over 80% of IGF-I is bound to a 150 kD protein whose synthesis is coordinately regulated predominately by growth hormone and 20 to 30% is bound to a 35-45 kD binding protein whose synthesis is not regulated by growth hormone. 
Additional evidence supporting a role of IGF-I in retinal neovascularisation is pro vided by clinical studies. In an initial study, Merrimee and colleagues24 reported elevated levels of IGF-I in serum of patients with rap idly accelerating diabetic retinopathy. Sub sequent studies by Kohner and colleagues25 refined this concept by showing that patients with preproliferative retinopathy who later went on to develop neovascularisation had significantly increased serum levels of IGF-I at the time of the first appearance of new ret inal vessels when compared to their serum IGF-I levels three months prior to the onset of their retinal vessel proliferation. Since vitreal levels of IGF-I may reflect the local environ ment of the retina more closely than serum levels, Grant and colleagues26 measured levels of IGF-I by RIA in vitreous samples of diabetic and nondiabetic patients. They reported 2-fold higher levels of IGF-I in vit reous from 23 patients with proliferative dia betic retinopathy compared to age matched control subjects (Fig. 2) . IGF-Il concentra tions in vitreous of diabetics and control sub jects were not significantly different. Thus, clinical results provide strong support for a role of vitreal IGF-I in development of retinal neovascularisation.
Epidermal Growth Factor and Transforming

Growth Factor alpha
Epidermal growth factor (EGF) and transfor ming growth factor alpha (TGF-ex) are mem bers of another family of angiogenic growth factors which also includes the proteins vac cinia growth factor and amphiregulin. 27-29 All these peptides possess a similar core structure of approximately 50 amino acids which con tain three intrachain disulfide loops. The amino acid sequence homology within this core structure is significantly conserved with approximately 35% direct sequence homol ogy between the members. All the factors can bind to and activate a 170,000 molecular weight, transmembrane, glycoprotein recep tor which possesses growth factor-activated tyrosine kinase activity in the cytoplasmic domain. Site directed mutations of the ATP binding site in the kinase domain have shown that all the major biological actions of the EGF receptor depend on the tyrosine kinase activity of the receptor. 3 0 Several physiological roles for EGF and TGF-ex have been proposed. Both are potent mitogens for a variety of different types of cells in culture including keratinocytes and fibroblasts. TGF-ex mRNA and protein, as well as the EGFffGF-ex receptor, are present in the basal layer of epidermal cells of the skin which suggests that TGF-ex is the primary fac tor responsible for normal growth of the epi dermis.3! EGF and TGF-(X are potent in hibitors of gastric acid secretion and stimulate mitosis of intestinal epithelium.
EGF and TGF-ex also have angiogenic actions. EGF stimulated neovascularisation in rabbit corneas when formulated in slow release polymers and placed in corneal pock ets,32 and EGF stimulated neovascularisation of embryonic'chick membranes.33 Both EGF and TGF-ex stimulated neovascularisation in the hamster cheek pouch assay,34 and were potent chemoattractants for rat heart endo thelial cells in culture. 35 Murine lung micro vascular endothelial cells and bovine pulmonary artery endothelial cells bound EGF and TGF-ex specifically, and increased DNA synthesis two to six fold in response to EGF and TGF-ex.34 EGFffGF-ex receptors also were detected in bovine retinal vessels by autoradiography of !25I_EGF binding, and TGF-ex protein and mRNA were detected in bovine retina (Fig. 3) .36 Thus, EGF and TGF-ex stimulate neovascularisation using in vitro and in vivo models. However, additional research needs to be performed to establish what role, if any, they play in vascular prolife rative diseases such as diabetic retinopathies.
Transforming Growth Factor beta
The newest family of neovascular peptide growth factors is the transforming growth fac tor beta family.37,38 TGF-�1 was originally purified from platelets and found to be a dimeric peptide composed of identical 112-amino acid subunits which are linked by dis ulfide bonds. Each monomer of the 25 kDA dimer is synthesised as a larger 390 amino acid pre-pro-TGF molecule that is proteolytically processed to a 361 amino acid pro-TGF-� form that dimerises to form a latent TGF-� dimer. Activation of the latent TGF-� dimer in vivo may be accomplished by proteolytic nicking by plasmin within the amino-terminal segment of the pro-TGF-� monomers which causes a disruption of tertiary structure and non covalent bonds that releases the active 25 kD TGF_�.39 It is now recognised that TGF-�1 belongs to a larger family of closely related genes that includes two closely related proteins in humans designated TGF-�2 and TGF-�3. Evaluations of recombinant TGF-Ws indicate that the proteins have very similar although not identical biological actions.
TGF-�1 can stimulate neovascularisation in vitro. Injection of TGF-�1 under the skin of mice led to fibrosis and neovascularisation at the site of injection which was characterised by an increase in macrophages, fibroblasts, and collagen formation.4 0 In contrast to these in vivo results, TGF-�1 strongly inhibited bFGF-induced proliferation and motility of fetal bovine heart endothelial cells in cul ture. 41 It is possible that the paradoxical effects of TGF-�1 in vivo are a result of an indirect effect of TGF-�1 on inflammatory cells in vivo. TGF-�l is an extremely potent chemoattractant (0.1 to 10 pg/ml) for periph eral blood monocytes at levels of TGF-�1 which are approximately 1,000 fold lower than the concentration reported to reduce DNA synthesis of heart endothelial cells in vitro. 42 Macrophages have been shown to syn thesise and secrete angiogenic peptide growth factors such as TGF-<x when activated. 43 Thus, it is possible that TGF-�1 initially attracted macrophages into the site of injection while also inhibiting endothelial cell division. Sub sequently, as the level of TGF-� decreases due to diffusion and degradation, the growth fac tors secreted by the macrophages stimulated neovascularisation.
The local effects of TGF-� on neovascular isation was also studied using an in vitro co culture system to mimic the interactions of endothelial cells and cells of the vessel wall.44 , 45 Conditioned medium from cultures of pericytes, smooth muscle cells, or endo thelial cells which were grown independently or in co-cultures wells that prevented cell con tact did not inhibit endothelial cell growth. In contrast, conditioned medium from co-cul tures of endothelial cells and pericytes grown in contact was strongly inhibitory to endo thelial cell growth. Acid activation of con ditioned medium from cultures of pericytes strongly inhibited endothelial cell growth indicating the presence of a latent inhibitor. Furthermore, either immunoadsorption of TGF-� from conditioned medium of co-cul tures or addition of neutralising anti-TGF-� antibody to co-cultures completely prevented pericyte-mediated inhibition of endothelial cell growth. These results suggest that growth of endothelial cells in vivo may be regulated by contact between pericytes and endothelial cells (Fig. 4) . Under normal conditions, latent TGF-� produced by pericytes appears to be activated by endothelial cells and acts to limit endothelial cell mitosis. If close contact between endothelial cells and pericytes,is lost, activation of latent TGF-� produced by per icytes is lost, and growth factors such as bFGF which are produced by endothelial cells act to stimulate endothelial cell mitosis and migration. It is possible that inhibitory factors like TGF-� are released from cells following laser treatment of neovascularised regions of the retina which contribute to the anti-angio genic effect of laser treatments for retinal neovascularisation.
Although TGF-� is perhaps best known for its ability to inhibit growth of many types of cells, TFG-� also stimulates in vitro growth of fibroblasts and synthesis of collagen. 4 0, 46 These actions have suggested that TGF-� may play a role in proliferative vitreoretinopathy (PVR). Vitreous aspirates from eyes with intraocular fibrosis associated with PVR had three times the average level of TGF-j3 than vitreous aspirates from eyes with uncompli cated retinal detachments without fibrosis. 47 Approximately 80 to 100% of the TGF-j3 activity in the vitreous samples could be blocked with antibodies specific for TGF-j32 whereas only 10 to 20% of the TGF-j3 activity could be blocked by antibodies specific for TGF-j3l. Thus, TGF-j3 peptides have complex biological actions in vivo, but their potent actions on key aspects of neovascularisation indicate that they will be important regulators of normal and abnormal neovascularisation in vivo.
Angiogenin
Angiogenin is a single chain peptide of 14,400 molecular weight with a pI of 9.5 that was first isolated from the conditioned medium of a human adenocarcinoma cell line.! It has approximately 35% amino acid sequence homology to pancreatic ribonuclease and is not related structurally to the heparin binding growth factors. Although angiogenin does stimulate neovascularisation in the chick embryo and rabbit cornea, it does not appear to be a mitogen for vascular endothelial cells in vitro. Since the target cell for angiogenin is not known, its mechanism of action has not yet been established and it remains to be determined whether angiogenin stimulates neovascularisation directly or indirectly by stimulating other cells to release angiogenic factors.
Pathological Neovascularisation and Peptide
Growth Factors
Understanding the roles various peptide growth factors play in regulating normal neo vascularisation is far from complete, but sub stantial progress has been made in establishing a molecular basis for many of the steps of neovascularisation which were pre viously understood only at a microscopic level. The ultimate clinical goal, however, is to prevent pathological neovascularisation from occurring. To accomplish this goal, it will be necessary to understand how the normal actions of peptide growth factor have been perturbed in the environment of a disease to ultimately cause pathological neovascularisation.
Focussing on diabetic retinopathy as an example of pathological neovascularisation, it is clear that fundamental biochemical changes begin early in the course of the diabetes and relentlessly progress to generate functional and structural changes in retinal tissue and blood cells that eventually initiate abnormal neovascularisation. As reviewed by Merri mee,48 prolonged hyperglcaemia causes alter ations in glucose metabolism leading to disturbances in levels of metabolites such as sorbitol and precursors of key regulatory mol ecules such as myo-inositol. Prolonged hyper glycaemia also causes anatomical changes such as thickening of basement membranes due to increased crosslinking of ECM pro teins by nonenzymatic glycosylation. Peri cyte . s are selectively lost from retinal capillaries, and sheer stress on endothelial cells is increased due to elevated blood vis cosity secondary to increased concentrations of several plasma proteins including fibrino gen, von Wille brand's factor, and thrombo spondin. Fundamental changes also occur in cellular constituents of blood including decreased red blood cell deform ability and hypercoagulability of platelets. These alter ations in extracellular matrix, blood cells, pericytes and endothelial cells combine to cre ate an environment of low perfusion and increased capillary permeability which eventually result in anoxia, injury to the ret ina, and leakage of blood proteins into the ret ina and finally into the vitreous. The retina appears to respond to this anoxia and injury by attempting to form new capillaries and re establish normal blood perfusion.
Peptide growth factors probably function late in the temporal sequence of the develop ment of diabetic retinopathy. It seems clear that peptide growth factors do not initiate the pathology which eventually leads to the anoxia and retinal injury. It seems equally clear, however, that peptide growth factors, which may be produced in the injured areas of the retina, act to stimulate the local neovas cularisation as they do in response to anoxia or injury under normal conditions. However, these new vessels have abberrant structure which results in abnormal function due to the lack of functional tight junction complexes, absence of pericytes, and scant basement membrane. The abberrant capillary tufts are very susceptible to leakage and rupture with minimal provocation resulting in vitreous haemorrhage. This induces more stimulation by growth factors and more abberrant neovascularisation.
As we begin to understand more about the role of peptide growth factors in normal and pathological neovascularisation it may become possible actively to intervene and control the process. Several key questions remain unanswered such as whether the ret inal neovascularisation that accompanies diabetes results from over stimulation by growth factors which promote vascularisation or due to an insufficient level of inhibitors of neovascularisation. What is the origin of the peptide growth factors? Are they primarily blood born or are they synthesised locally by the retinal vascular endothelial cells, retinal pigmented epithelial cells, or glial cells? Can neovascularisation be accomplished without formation of defective capillaries? Answers to these and other questions may become the basis for new therapeutic approaches which are now possible because of the availability of biochemically well-characterised neovascular peptide growth factors.
